Last Update: 08/28/2007 Printer Friendly Printer Friendly   Email This Page Email This Page  

International Maternal-Pediatric-Adolescent AIDS Clinical Trials (IMPAACT) Group

The IMPAACT group represents a merger of the Pediatric AIDS Clinical Trials Group (PACTG) and the Perinatal Scientific Working Group of the HIV Prevention Trials Network (HPTN).

The PACTG/NICHD Network collaboration, supported by the National Institute on Allergy and Infectious Diseases (NIAID)and by the NICHD Pediatric, Adolescent, and Maternal AIDS (PAMA) Branch, has been the principal means for conducting clinical trials of HIV treatment in children worldwide. Similarly, the HPTN, supported by NIAID and previously supported through the PAMA Branch, has been the primary group conducting clinical trials of interventions to prevent HIV mother-to-child transmission in international settings. Taken together, the activities of these two networks represent a major component of cross-Institute collaboration between the NICHD and the NIAID.

Through its efforts with IMPAACT, the PAMA Branch will continue its long-standing collaboration with NIAID on pediatric studies by funding non-overlapping domestic and international clinical trials sites.

IMPAACT projects seek to:

  • Develop and evaluate safe and effective approaches to prevent mother-to-infant transmission of HIV;
  • Evaluate treatment for HIV-infected children, adolescents, and pregnant women, including treatment and prevention of co-infections; and
  • Evaluate vaccines for the prevention of HIV transmission among adolescents.

For more information on IMPAACT, visit http://www3.niaid.nih.gov/about/organization/daids/Networks/daidsnetworks.htm.